Venture Café – Marco Colona, MD and David Holtzman, MD Present: Translating Genetic Insights Into Treatments for Alzheimer’s Disease

October 15, 2020
4:00 pm - 4:45 pm
Venture Café Virtual,

Precision Medicine Thursdays at Venture Café

Attendance is FREE and open to all.


Marco Colonna, MD

Professor of Immunobiology, Washington University School of Medicine

Harnessing TREM2 in the Therapy of Neurodegeneration

If you would like to discuss this talk with Dr. Colonna, he can be reached at

David Holtzman, MD

Andrew  B & Gretchen P Jones Professor of Neurology, Washington University School of Medicine

Importance of APOE for Alzheimer’s disease        

The Apolipoprotein E gene is the strongest genetic risk factor for Alzheimer’s disease (AD).  ApoE comes in 3 “flavors” in humans, apoE2, apoE3, and apoE4.  Each of us carries 2 copies of the apoE gene.  ApoE4 strongly increases AD risk and apoE2 decreases risk relative to apoE3.  Data will be presented showing that apoE influences the major pathologies underlying AD including amyloid plaques, neurofibrillary tangles, and inflammation.  Decreasing the levels of apoE4 promises to be a way to decrease risk as well as to slow down the progression of cognitive decline due to AD.

If you would like discuss this talk with Dr. Holtzman, he can be reached here:


On the third Thursday of every month, ICTS Precision Medicine hosts a session featuring WashU faculty working in translational genomics/precision medicine areas. Talks are typically oriented toward biotechnology, diagnostics, informatics, start-ups and precision interventions based on medical genomics innovations.